PATENT CLAIM ANALYSIS

Application Number: 15769079
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "337000"]

Abstract:
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B 4  receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B 4  receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

Claim (Index 19):
The compound according to  claim 1  selected from:\n (1) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-((5-(thiazol-5-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (2) 1,1,1-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-((5-(thiazol-5-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (3) 1,1,1-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-((5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (4) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-((5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (5) 1,1,1-Trifluoro-N-(2-((3,4-trans)-4-hydroxy-3-((5-(1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (6) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-((5-(5-methylthiazol-2-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (7) 1,1,1-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-((5-(5-methylthiazol-2-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (8) 1,1,1-trifluoro-N-{4-fluoro-2-[(rac-trans) 4-hydroxy-3-{[5-(1,3-thiazol-5-yl)pyridin-2-yl]methyl}-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; \n (9) 1,1,1-Trifluoro-N-(2-((3,4-trans)-4-hydroxy-3-((5-(thiazol-4-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (10) 1,1,1-Trifluoro-N-(2-((3,4-trans)-4-hydroxy-3-((5-(thiazol-2-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (11) 1,1,1-Trifluoro-N-(2-((3,4-trans)-4-hydroxy-3-((5-(thiazol-2-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (12) 1,1,1-Trifluoro-N-(2-((3,4-trans)-4-hydroxy-3-((5-(thiazol-4-yl)pyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; \n (13) 1,1,1-trifluoro-N-{4-fluoro-2-[(3S,4R)-4-hydroxy-3-{[5-(1,3-thiazol-5-yl)pyridin-2-yl]methyl}-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; and \n (14) 1,1,1-trifluoro-N-{4-fluoro-2-[(3R,4S)-4-hydroxy-3-{[5-(1,3-thiazol-5-yl)pyridin-2-yl]methyl}-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; \n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 91.0
- Lexical Diversity: 1.7069
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15767371', '15768097', '12210247', '13371834', '10481352']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7823216318261405
- 35 USC 102 Novelty (BERT): 0.5945968583154205
- Combined Prediction Score: 0.7635491544750684
- Mean Citation Score: 385.288128
- Max Citation Score: 501.19183
- Similarity Product: 441.5193134457468

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test